A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

NCT02032277 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

634

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Cyclophosphamide
DRUG: Placebo
DRUG: Doxorubicin
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Veliparib
DRUG: Placebo

Sponsor

AbbVie

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]